Novo Nordisk Q1 2026 report has officially been released, painting a picture of the explosive wave of GLP-1 demand. Published on May 6, 2026, the earnings data revealed a significant revenue beat of $14.97 billion (DKK 96.8 billion), easily surpassing the anticipated $11.17 billion. This 32% growth at constant exchange rates (CER) was heavily bolstered by the historic U.S. launch of the oral Wegovy pill and a one-time provision reversal related to the 340B Drug Pricing Program.
Key Takeaways from the Novo Nordisk Q1 2026 Report
A deep dive into the financials shows a fascinating dichotomy between reported and adjusted figures. While reported net sales soared, adjusted sales, which exclude the one-time 340B provision reversal, actually declined by 4% at CER, largely due to ongoing pricing pressures in the legacy U.S. diabetes market. However, investors focused on the positives, sending the stock up nearly 6% in pre-market trading following the release of the Novo Nordisk Q1 2026 report.
The indisputable star of the quarter was the Wegovy pill. Launched in the U.S. on January 5, 2026, the oral medication brought in DKK 2.26 billion ($353 million) in its first quarter, crushing analyst estimates. According to CEO Mike Doustdar, total prescriptions surpassed 1.3 million in Q1 alone, marking the strongest-ever GLP-1 volume launch in the United States.
How the Novo Nordisk Q1 2026 Report Impacts the Future Outlook
Given the massive consumer uptake, Novo Nordisk has officially raised its 2026 full-year outlook. The company expects the continued global rollout of the Wegovy pill, with international launches scheduled for the second half of 2026, to offset the margin compressions seen in its insulin divisions.
High-Level Financial Performance (Q1 2026)
| Financial Metric | Q1 2026 Reported Value | Year-over-Year Growth (CER) | Notes / Context |
| Total Net Sales | DKK 96.82 billion ($14.97B) | +32% | Positively impacted by 340B provision reversal in the US. |
| Adjusted Net Sales | DKK 70.06 billion | -4% | Excludes 340B provision reversal; impacted by lower realised prices. |
| Operating Profit | DKK 59.62 billion | +65% | Strong reported increase tied to non-recurring items. |
| Adjusted Operating Profit | DKK 32.86 billion | -6% | Reflects pricing pressure and high R&D/commercial investments. |
| Free Cash Flow | DKK 12.77 billion | N/A | Supported by strong top-line revenue collection. |
Sales by Therapy Area & Key Brands (Q1 2026)
| Segment / Brand | Q1 2026 Sales (DKK million) | Growth at CER | Highlights |
| Total Obesity Care | 20,912 | +22% | Driven by surging global demand for weight-management GLP-1s. |
| Total Diabetes Care | 44,936 | -12% | Facing persistent pricing pressure in the US market. |
| Wegovy® (Injectable) | 18,235 | +12% | Continued steady growth despite supply chain focus on oral rollout. |
| Wegovy® (Pill) | 2,256 | N/A (New Launch) | Launched Jan 5, 2026; over 1.3M total prescriptions in Q1. |
| Ozempic® | 27,825 | -8% | Experienced slight headwinds from pricing, though volume remains high. |
| Rare Disease | 4,215 | -2% | Minor decline overall, though rare endocrine products gained 93%. |
Regional Dynamics in the Novo Nordisk Q1 2026 Report
The Novo Nordisk Q1 2026 report highlights a significant divergence between U.S. and International operations. U.S. sales were bolstered by a one-time DKK 26.7 billion provision reversal related to the 340B Drug Pricing Program. However, on an adjusted basis, U.S. sales actually declined by 11% due to intensified pricing competition in the diabetes sector.
Conversely, International Operations remained a stronghold of organic growth, expanding by 6% at CER. Markets like EUCAN (Europe & Canada) and APAC (Asia-Pacific) led this charge, with growth rates of 23% and 22% respectively, offsetting contractions in Emerging Markets.
Clinical Breakthroughs and Regulatory Milestones
Innovation remains the bedrock of the company’s long-term value. The Novo Nordisk Q1 2026 report confirmed several landmark regulatory wins:
- Wegovy® HD (7.2 mg): FDA approval in March 2026, offering 20.7% mean weight loss.
- Awiqli®: The first-ever once-weekly basal insulin for Type 2 diabetes received FDA clearance.
- Etavopivat: Successfully met co-primary endpoints in the HIBISCUS Phase 3 trial for Sickle Cell Disease.
Regional Sales Breakdown (Q1 2026)
| Geographic Region | Adjusted Sales (DKK million) | Growth at CER | Market Dynamics |
| Total International Operations | 32,042 | +6% | Strong volume growth across all therapy areas. |
| – EUCAN | 16,845 | +23% | High demand for obesity treatments in Europe. |
| – APAC | 5,821 | +22% | Expansion in Japan and South Korea. |
| – Region China | 6,104 | -10% | Impacted by VBP (Volume-Based Procurement) pricing. |
| – Emerging Markets | 3,272 | -18% | Currency volatility and supply chain adjustments. |
| US Operations (Adjusted) | 38,021 | -11% | Impacted by 70% average rebate levels in US Diabetes. |
Clinical Pipeline Progress (Q1 2026)
| Asset / Product | Phase / Status | Therapeutic Area | Key Achievement |
| Wegovy® HD (7.2 mg) | Approved (US) | Obesity | 20.7% mean weight loss in STEP UP trial. |
| Awiqli® (Icodec) | Approved (US) | Diabetes | First once-weekly insulin for T2D. |
| Etavopivat | Phase 3 Complete | Sickle Cell | Met co-primary endpoints; 27% VOC reduction. |
| Denecimig (Mim8) | Phase 3 Data | Haemophilia A | Significantly reduced annualized bleeding rates. |
| UBT251 (Triple Agonist) | Phase 2 | T2D / Obesity | 2.16% HbA1c reduction in Chinese patient trials. |
Revised Full-Year 2026 Financial Guidance
| Metric | New 2026 Guidance (CER) | Previous Guidance (CER) |
| Adjusted Sales Growth | -4% to -12% | -5% to -13% |
| Adjusted Operating Profit Growth | -4% to -12% | -5% to -13% |
| Reported Sales Growth (Midpoint) | ~1% | N/A |
| Reported Operating Profit (Midpoint) | ~12% | N/A |
| Capital Expenditure (CAPEX) | DKK 60 billion | DKK 55 billion |
Pfizer Sigvotatug Vedotin Phase 3 Topline Results Released for Lung Cancer
Pfizer has announced topline Phase 3 results from its SigVie-002 study evaluating the investigational antibody-drug conjugate sigvotatug vedotin in previously treated metastatic non-squamous non-small cell […]
AbbVie to Acquire Apogee Therapeutics to Advance Zumilokibart (APG777) in $10.9 Billion Portfolio Expansion
AbbVie and Apogee Therapeutics have announced a definitive $10.9 billion acquisition agreement. The transaction enhances AbbVie's global immunology portfolio by adding advanced assets like zumilokibart […]
AbbVie Apogee Therapeutics Acquisition Nears: $10.9 Billion Deal Packages Lead Eczema Drug Zumilokibart
Pharmaceutical titan AbbVie is in advanced discussions to purchase anti-inflammatory biotech developer Apogee Therapeutics for $10.9 billion in cash, marking its most significant bolt-on transaction […]
Capital Allocation & Shareholder Returns
| Allocation Type | Q1 2026 Amount (DKK) | Full-Year 2026 Target |
| Total Cash Returned | 37.7 billion | >60 billion |
| Dividends Paid | 35.3 billion | N/A |
| Share Buybacks | 2.4 billion | Up to 15 billion (Program total) |
| R&D Investment | 10.3 billion | Continued expansion in AI & Triple Agonists |
Last Modified:
